A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - A phase I clinical trial.

Front Med (Lausanne) · 2022 · PMC9621317 · PMID 36325389

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Vitreal haze in the 0.3 μg group had increased on day 2 and showed a trend toward improvement in the follow up, also in the 0.6 μg group with an improvement by one step on the SUN scale.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.